Valence ロゴ
人気
ログイン
Loading data for PCVX — first visit, this takes a few seconds.

ウォッチリストに追加

Vaxcyte Inc.

NasdaqGS: PCVX · リアルタイム株価 · USD
62.62
+1.28 (2.09%)
終値時点： Aug 21, 2026, 8:00 PM
62.85
+0.37%
時間外: 7:30 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

Vaxcyte Inc.（PCVX）の株価・分析・データ

2.09%

データがありません

買気配45.12
時価総額9.32B
売上高（TTM）n/a
純利益（TTM）-1.06B
1.21
-7.63
n/a
-8.68
PBR（TTM）3.29
PSR（TTM）n/a
決算発表日Nov 3, 2026
売気配79.48
出来高1,127,190
平均出来高（20日）1,356,848
始値61.85
前日終値61.34
当日レンジ61.85 - 63.98
52週レンジ29.87 - 65.00
アナリストn/a
目標株価n/a
配当n/a
権利落ち日n/a

PCVXについて

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of...

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Jun 12, 2020
従業員数 507
上場取引所 NasdaqGS
ティッカー PCVX
ウェブサイト https://vaxcyte.com
企業情報の全文

業績

2025年のVaxcyteの売上高は0で、前年の0からundefined%の増加でした。 利益は-766.63Mで、65.25%の増加でした。

財務諸表

決算サプライズ

VaxcyteはAug 5, 2026に四半期決算を発表しました：
  • 売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.
  • EPSは -1.97 で、予想を上回りました 0.13, うち -61.48% の前年比減少.

次回決算発表

Vaxcyte Inc.の決算発表予定日は Nov 3, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード
news image

6日前 · 24/7 Wall St.

If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone

Retail investors who spotted Seth Klarman buying Vaxcyte in May were already two months behind a trade Baupost had quietly begun unwinding. Understanding exactly what got lost in that gap changes how ...

news image

1か月前 · Insider Monkey

Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now

Vaxcyte Inc. (NASDAQ:PCVX) is one of the 8 Hidden Multibagger Stocks to Buy Now. On June 18, Mizuho Securities analyst Salim Syed reiterated a Buy rating on Vaxcyte Inc. (NASDAQ:PCVX) with a price tar...

news image

2か月前 · Insider Monkey

Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the most promising healthcare stocks according to Wall Street analysts. On June 2, Vaxcyte, Inc. (NASDAQ:PCVX) dosed the first participant in its Phase 1 first-in...

news image

2か月前 · Insider Monkey

Vaxcyte (PCVX) Conducts Initial Dosage for VAX-A1 Phase 1 Study

Vaxcyte Inc. (NASDAQ:PCVX) is one of the 10 best mid-cap stocks that could double your money. On June 3, Vaxcyte Inc. (NASDAQ:PCVX) announced that the first participant was dosed in the Phase 1, first...

news image

2か月前 · Motley Fool

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.

This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.

2ページ中1ページ